BCHE and early-onset autosomal dominant Alzheimer disease: Inhibitors of acetylcholinesterase/cholinesterase, which represent the primary category of pharmacological agents currently employed in the therapeutic management of AD, are incapable of fully arresting the progression of Alzheimer’s disease.